Rani Therapeutics Holdings Inc (RANI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.86 (+0.49%), Market cap $0.12B, 52-week low–high $0.41 ~ $2.85.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111,
Financial statements, price targets, institutional (13F) holdings and related news for Rani Therapeutics Holdings Inc are updated in real time on BlackAll Trade.
Rani Therapeutics Holdings Inc trades at $0.86 (+0.49%). Real-time quotes and charts are available on BlackAll Trade.
Rani Therapeutics Holdings Inc has a market cap of about $0.12B.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and